SCHEMBL969678

SCHEMBL969678

CCCc1c[nH]cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
PTPN1 P18031 2/20 0.42
PTPN11 Q06124 1/20 0.42
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
RXRA P19793 2/20 0.38
HCAR2 Q8TDS4 1/20 0.38
MCL1 Q07820 1/20 0.38
GABRP O00591 3/20 0.37
GABRD O14764 3/20 0.37
GABRA1 P14867 3/20 0.37
GABRB1 P18505 3/20 0.37
GABRG2 P18507 3/20 0.37
GABRB3 P28472 3/20 0.37
GABRA5 P31644 3/20 0.37
GABRA3 P34903 3/20 0.37
GABRA2 P47869 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21751965 0.85 NOTUM (0.54) NOTUMKDM5AKDM5BKDM4EALDH1A1
SCHEMBL5842251 0.81 NOTUM (0.45) NOTUMPTPN1KDM5AKDM5BKDM4E
SCHEMBL1155956 0.79 ALDH1A1 (0.40) KDM4EALDH1A1KMT2APPARAHTT
SCHEMBL4527898 0.77 KMT2A (0.49) KDM4EALDH1A1KMT2ACA12CA9
SCHEMBL7260781 0.77 PRKCI (0.34) PTPN1PTPN11KDM4EALDH1A1HCAR2
SCHEMBL1126724 0.73 NOTUM (0.47) NOTUMALDH1A1KMT2AGABRA1GABRB2
Isobutyramide SCHEMBL28976391 0.73 NOTUM (0.39) NOTUMALDH1A1KMT2A
SCHEMBL28270009 0.73 EPHX2 (0.36) PTPN1PTPN11ALDH1A1KMT2AHCAR2
SCHEMBL70047 0.71 NOTUM (0.65) NOTUMKDM4EALDH1A1KMT2ACA12
SCHEMBL5154187 0.71 PTPN1 (0.46) PTPN1PTPN11KDM5AKDM5BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875745-B2 {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-25 US disclosed
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
EP-0231394-B1 NOVEL POLYMERS OF3,4-SUBSTITUTED PYRROLE COMPOUND AND PROCESSFOR THEIR PREPARATION NIPPON SODA CO., LTD. (JP) 1991-03-13 EP disclosed
US-4816536-A ELECTROCHROMISM ELEMENTS NIPPON SODA CO., LTD. (JP) 1989-03-28 US disclosed
EP-0231394-A1 NOVEL POLYMERS OF3,4-SUBSTITUTED PYRROLE COMPOUND AND PROCESSFOR THEIR PREPARATION NIPPON SODA CO., LTD. (JP) 1987-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof LPAR2, LPAR1, LPAR5 NOTUM 3884/4885PTPN1 930/4885PTPN11 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.